drugset / Trial / NCT00176839
Stem Cell Transplantation for Hematological Malignancies
NaSingle-groupOpen-labelTreatment
Summary
This protocol using busulfan, cyclophosphamide and melphalan has been designed as conditioning therapy for patients receiving stem cell transplantation for acute leukemia or myelodysplastic syndrome (MDS). The hypothesis is that this new regimen will be well tolerated and will cure the patient.
Timeline
- Start
- 2000-06-07
- Primary completion
- 2012-02
- Completion
- 2012-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | ATG | Unknown | — | — |
| Background | Busulfan | Small molecule | — | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | 60 mg/kg | Intravenous |
| Background | G-CSF | Unknown | — | Intravenous |
| Background | Melphalan | Small molecule | 140 unknown | Intravenous |